CD8A and renal cell carcinoma: Similarly, upregulation of SLC2A3 could enhance CD28 costimulation reprogrammed renal cell carcinoma CD8+ TIL metabolism, which is antagonized by the inhibitory and checkpoint immunotherapy receptors CTLA4 and PD-1 [52].